← Leaderboards
Denise Martin Adams
Cincinnati Childrens Hosp Med Ctr
$2,577,396
Attributed
$2,600,313
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,696,735 · 3
FDA$1,762,806 · 2
By mechanism
U54$2,669,235 · 2
R01$1,762,806 · 2
R13$27,500 · 1
Top collaborators
- Yvonne E Chiu1 shared
- Beth A Drolet1 shared
- Kelly J Duffy1 shared
- Maria C Garzon1 shared
- Michael Jeng1 shared
- Michael E Kelly1 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Katherine E Yutzey$22,408,688
- Jason F Woodward$456,000
- Jareen Meinzen-Derr$4,869,637
- Timothy David Le Cras$5,210,029
- James Cnota$9,943,565
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchCollaborationsBlood VesselsScientistHemorrhageInnovationInvestigationCommunicationFosteringFamilyGrantAwarenessAgreementInfrastructureClinical InfrastructureClinical Trial ReadinessChildCareerAreaClinical CareClinical TrialsDiagnosisFutureFunding
Grant awards (9)
ARDVARC-Advancing Rare Disorders: Vascular mAlformation Research Network with CaNVAS$1,859,228
U54 · FY2025 · HL · contact PI
ARDVARC-Advancing Rare Disorders: Vascular mAlformation Research Network with CaNVAS: Admin Core$810,007
U54 · FY2025 · HL · contact PI
Phase 2 Study of Vincristine vs. Sirolimus for the Treatment of High Risk Kaposiform Hemangioendothelioma$141,587
R01 · FY2016 · FD · contact PI
Phase 2 Study of Vincristine vs. Sirolimus for the Treatment of High Risk Kaposiform Hemangioendothelioma$258,413
R01 · FY2014 · FD · contact PI
Phase II Study of Rapamycin for Complicated Vascular Anomalies IND Exempt$344,481
R01 · FY2012 · FD · contact PI
Phase II Study of Rapamycin for Complicated Vascular Anomalies IND Exempt$342,760
R01 · FY2011 · FD · contact PI
Interdisciplinary Workshop on Vascular Anomalies Associated with Coagulopathies$27,500
R13 · FY2011 · AR
Phase II Study of Rapamycin for Complicated Vascular Anomalies IND Exempt$338,853
R01 · FY2010 · FD · contact PI
Phase II Study of Rapamycin for Complicated Vascular Anomalies IND Exempt$336,712
R01 · FY2009 · FD · contact PI